Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke

Diabetes, Obesity and Metabolism

Volumn 17, Issue 12, 2015, Pages 1194-1197

  Floyd, James S ^a,b   Wiggins, K L ^a   Sitlani, C M ^a,b   Flory, J H ^c,d   Dublin, S ^b,e   Smith, N L ^a,b,e,f   Heckbert, S R ^a,b,e   Psaty, B M ^a,b,e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e GROUP HEALTH RESEARCH INSTITUTE   (United States)

^f DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Cardiovascular outcomes; Case control study; Comparative safety; Insulin; Metformin; Myocardial infarction; Stroke; Sulphonylureas

Indexed keywords

INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

ADULT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; POPULATION BASED CASE CONTROL STUDY; ADVERSE EFFECTS; AGED; CASE CONTROL STUDY; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; INCIDENCE; MEDICAL RECORD; MIDDLE AGED; MYOCARDIAL INFARCTION; PRACTICE GUIDELINE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STROKE; WASHINGTON;

AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; MALE; MEDICAL RECORDS; METFORMIN; MIDDLE AGED; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES AS TOPIC; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROKE; SULFONYLUREA COMPOUNDS; WASHINGTON;

EID: 84945266611     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12537     Document Type: Letter

References (14)

1. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
2. Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014; 383: 2008-2017.
3. Roumie CL, Greevy RA, Grijalva CG et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA 2014; 311: 2288-2296.
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
5. Boger-Megiddo I, Heckbert SR, Weiss NS et al. Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study. BMJ 2010; 340: c103.
6. Schafer JL. Analysis of Incomplete Multivariate Data. Boca Raton: Chapman & Hall/CRC, 1997.
7. Miettinen O. Estimability and estimation in case-referent studies. Am J Epidemiol 1976; 103: 226-235.
8. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991; 10: 1665-1677.
9. Weiss NS. All-cause mortality as an outcome in epidemiologic studies: proceed with caution. Eur J Epidemiol 2014; 29: 147-149.
10. Gerstein HC, Bosch J, Dagenais GR et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328.
11. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19(Suppl.): 789-830.
12. Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
13. Nathan DM, Buse JB, Kahn SE et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care 2013; 36: 2254-2261.
14. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010; 33: 1389-1394.